Inhibition of HIF-1α by Atorvastatin During (131)I-RTX Therapy in Burkitt’s Lymphoma Model

Backgrounds: Radioimmunotherapy (RIT) serves as a targeted therapy for non-Hodgkin lymphomas (NHL). Although HIF(Hypoxia-inducible factors)-1α is an important biomarker during radiation therapy, its role in NHL is unclear. Atorvastatin (ATV) is used as a combination drug for chemotherapy. Methods: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Eun-Ho, Ko, Hae Young, Yu, A Ram, Kim, Hyeongi, Zaheer, Javeria, Kang, Hyun Ji, Lim, Young-Cheol, Cho, Kyung Deuk, Joo, Hyun-Yoo, Kang, Min Kyoung, Lee, Jae Jun, Lee, Seung-Sook, Kang, Hye Jin, Lim, Sang Moo, Kim, Jin Su
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281655/
https://www.ncbi.nlm.nih.gov/pubmed/32403237
http://dx.doi.org/10.3390/cancers12051203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7281655/
https://www.ncbi.nlm.nih.gov/pubmed/32403237
http://dx.doi.org/10.3390/cancers12051203

Ejemplares similares